Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for February 1, 2022

2/1/2022

 
Regulatory Update
 
The FDA approved faricimab (Vabysmo, Genentech/Roche), on 1/28/2022, to treat diabetic macular edema and neovascular age-related macular degeneration.
 
The FDA approved tebentafusp (Kimmtrak, Immunocore), on 1/26/2022, for the treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma. Tebentafusp was approved with a black boxed warning for cytokine release syndrome.
 
Provention Bio satisfied FDA concerns for the dosing and equivalence of the AGC Biologics manufactured templizumab. A new BLA submission will also address Chemical, Manufacturing, and Controls (CMC) and product quality questions from the FDA rejection in 2021. Provention Bio plans to resubmit a BLA for templizumab in 1Q22.
 
Incyte has discontinued its request for accelerated approval of parsaclisib for the treatment of relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma, because the company felt it would be too difficult to complete required confirmatory studies to convert the accelerated approval to a full approval.
 
The FDA paused trials evaluating the combination of magrolimab and azacitidine due to adverse reactions seen with the combination. The pause did not affect trials evaluating magrolimab alone or in combination with other chemotherapy.
 
The FDA placed a partial hold on studies evaluating the combination of umbralisib and ublituximab in the treatment of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
 
The FDA designated eplontersen an Orphan Drug for the treatment of transthyretin-mediated amyloidosis.
 
Announced Research Updates
 
Sierra announced results of the MOMENTUM trial evaluating momelotinib in the treatment of myelofibrosis.
 
Madrigal announced results from the MAESTRO-NAFLD-1 trial where resmetirom was evaluated for the treatment of NASH.
 
Published Research Updates
 
Delgocitinib was evaluated in a Phase IIb chronic hand eczema trial
 
Plinabulin was compared to pegfilgrastim to prevent grade 4 neutropenia in the PROTECTIVE-1 trial.
 
The BrighTNess trial evaluated the effect of adding veliparib to carboplatin in patients with triple-negative breast cancer.
 
Check out our new lower subscription rates and don't miss out on these clinical updates.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.